Browse CXCL12

Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemoattractant active on T-lymphocytes and monocytes but not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a reduced chemotactic activity. Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites. Also binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. Binds to the allosteric site (site 2) of integrins and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 in a CXCR4-independent manner (PubMed:29301984). Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. Stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1, a ligand for beta-2 integrins. SDF1A/CXCR4 signaling axis inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to ICAM-1 through LYN kinase. Inhibits CXCR4-mediated infection by T-cell line-adapted HIV-1. Plays a protective role after myocardial infarction. Induces down-regulation and internalization of ACKR3 expressed in various cells. Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation. Stimulates the proliferation of bone marrow-derived B-cell progenitors in the presence of IL7 as well as growth of stromal cell-dependent pre-B-cells (By similarity).

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001666 response to hypoxia
GO:0001764 neuron migration
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002548 monocyte chemotaxis
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002686 negative regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002691 regulation of cellular extravasation
GO:0002692 negative regulation of cellular extravasation
GO:0003013 circulatory system process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007015 actin filament organization
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007626 locomotory behavior
GO:0008015 blood circulation
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0008344 adult locomotory behavior
GO:0008361 regulation of cell size
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009266 response to temperature stimulus
GO:0009314 response to radiation
GO:0009408 response to heat
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010959 regulation of metal ion transport
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014046 dopamine secretion
GO:0014059 regulation of dopamine secretion
GO:0015837 amine transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015872 dopamine transport
GO:0016049 cell growth
GO:0021537 telencephalon development
GO:0021885 forebrain cell migration
GO:0022029 telencephalon cell migration
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022604 regulation of cell morphogenesis
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0030516 regulation of axon extension
GO:0030534 adult behavior
GO:0030595 leukocyte chemotaxis
GO:0030832 regulation of actin filament length
GO:0030900 forebrain development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031346 positive regulation of cell projection organization
GO:0032103 positive regulation of response to external stimulus
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033603 positive regulation of dopamine secretion
GO:0033605 positive regulation of catecholamine secretion
GO:0036293 response to decreased oxygen levels
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0043270 positive regulation of ion transport
GO:0043434 response to peptide hormone
GO:0044708 single-organism behavior
GO:0045123 cellular extravasation
GO:0045666 positive regulation of neuron differentiation
GO:0045773 positive regulation of axon extension
GO:0045785 positive regulation of cell adhesion
GO:0045927 positive regulation of growth
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048841 regulation of axon extension involved in axon guidance
GO:0048842 positive regulation of axon extension involved in axon guidance
GO:0048846 axon extension involved in axon guidance
GO:0050432 catecholamine secretion
GO:0050433 regulation of catecholamine secretion
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0050900 leukocyte migration
GO:0050901 leukocyte tethering or rolling
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0050930 induction of positive chemotaxis
GO:0051047 positive regulation of secretion
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0051937 catecholamine transport
GO:0051952 regulation of amine transport
GO:0051954 positive regulation of amine transport
GO:0051962 positive regulation of nervous system development
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0060560 developmental growth involved in morphogenesis
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0061756 leukocyte adhesion to vascular endothelial cell
GO:0070098 chemokine-mediated signaling pathway
GO:0070482 response to oxygen levels
GO:0070509 calcium ion import
GO:0070838 divalent metal ion transport
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071887 leukocyte apoptotic process
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090066 regulation of anatomical structure size
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097485 neuron projection guidance
GO:0097529 myeloid leukocyte migration
GO:1901652 response to peptide
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902284 neuron projection extension involved in neuron projection guidance
GO:1902532 negative regulation of intracellular signal transduction
GO:1902667 regulation of axon guidance
GO:1902669 positive regulation of axon guidance
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903236 regulation of leukocyte tethering or rolling
GO:1903237 negative regulation of leukocyte tethering or rolling
GO:1903532 positive regulation of secretion by cell
GO:1904994 regulation of leukocyte adhesion to vascular endothelial cell
GO:1904995 negative regulation of leukocyte adhesion to vascular endothelial cell
GO:1990138 neuron projection extension
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0008083 growth factor activity
GO:0042056 chemoattractant activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04360 Axon guidance
hsa04670 Leukocyte transendothelial migration
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-1236394: Signaling by ERBB4
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL12 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28274958Prostate CarcinomaInhibit immunityThis was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor.
25320277Ovarian CarcinomaInhibit immunity (T cell function)CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
22710190Gastric CarcinomaInhibit immunity (T cell function)Supernatants from cultured Tc17 cells induced production of the chemokine CXCL12 by tumor cells; this promoted CXCR4-dependent migration of MDSCs and impaired functions of anti-tumor CD8(+) cytotoxic T cells via a cell contact-dependent mechanism.
29379494Chronic Lymphocytic LeukemiaInhibit immunity (T cell function); immunotherapy targetHere, we show that the CXC chemokine ligand 12 (CXCL12)-CXCR4-STAT3 axis regulates IL-10 production by CLL cells and their ability to suppress T-cell effector function through an IL-10 mediated mechanism. We conclude that the capacity of CLL cells to produce IL-10 is mediated by the CXCL12-CXCR4-STAT3 pathway and likely contributes to immunodeficiency in patients.
18354188Malignant Skin NeoplasmInhibit immunity; immunotherapy targetMast cells express CXCR4(+) and UV exposure up-regulated the expression of its ligand CXCL12 by lymph node B cells. Treating UV-irradiated mice with a CXCR4 antagonist blocked mast cell migration and abrogated UV-induced immune suppression.
16493048MelanomaInhibit immunity (T cell function)Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. We proposed that repulsion of tumor Ag-specific T cells from a tumor expressing high levels of CXCL12 allows the tumor to evade immune control.
23514705Pancreatic CarcinomaInhibit immunity (T cell function)Luminex analysis indicated that PSC but not human fetal primary pancreatic fibroblast cells (HPF; negative controls) produced MDSC-promoting cytokines [interleukin (IL-6), VEGF, macrophage colony-stimulating factor (M-CSF) ] and chemokines (SDF-1, MCP-1).
21159639LymphomaInhibit immunity (T cell function)CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. In vivo blocking identified the CXCR4/CXCL12 axis as being critical for Treg attraction toward BCL. In contrast to Tregs, effector T cells displayed low levels of CXCR4 and were not affected by the pharmacologic blockade. Most important, blocking CXCR4 not only reduced Treg migration toward tumor tissue but also enhanced antitumor responses after alloHCT.
29036438Gastric CarcinomaInhibit immunity (T cell function)We generated a xenograft mouse model and used SEW-2871, a S1P1 specific agonist to activate S1P1 signalling. SEW-2871 promoted tumor growth in our mouse model, and induced a higher level of MDSC and a reduced level of CD8+CD69+ T cells within tumor. Additionally, SEW-2871 enhanced expression of several MDSC recruitment-associated chemokines (CXCL12, CXCL5 and CCL2) in tumor cells. These chemokines facilitated MDSC migration by interaction with CCR2, CXCR2 and CXCR4. S1P1 signalling promoted gastric cancer by enhancing chemokine expression in tumor cells and recruiting MDSC to tumor microenvironment, which impaired anti-tumoral function of TILs.
27593937Hepatocellular CarcinomaInhibit immunity (T cell function); immunotherapy targetTumor-associated fibroblasts (TAFs) attracted monocytes by the stromal cell-derived factor (SDF)-1a/CXCR4 pathway and induced their differentiation into MDSCs through interleukin (IL)-6-mediated STAT3 activation. Together, our results are the first to show that TAF-derived cytokines, such as IL-6 and SDF-1a, can induce MDSC generation and activation and then impair human anti-tumor immune responses, which create favorable conditions for HCC progression. Consequently, methods in which immunotherapy is combined with IL-6, SDF-1a or STAT3 inhibition may offer an improved option to eliminate suppressive CD11b+ myeloid cells in HCC patients.
23804711Chronic Lymphocytic LeukemiaInhibit immunityTransendothelial migration (TEM) of normal lymphocytes into lymph nodes requires the chemokine-induced activation of Rap1 and αLβ2 integrin. However, in most cases of CLL, Rap1 is refractory to chemokine stimulation, resulting in failed αLβ2 activation and TEM unless α4β1 is coexpressed. In this study, we show that the inability of CXCL12 to induce Rap1 GTP loading in CLL cells results from failure of Rap1-containing endosomes to translocate to the plasma membrane. Taken together, our findings indicate that chemokine unresponsiveness in CLL lymphocytes results from failure of Arf1/phospholipase D1-mediated translocation of Rap1 to the plasma membrane for GTP loading and may be a specific feature of anergy induced by DNA Ags.
20849618Breast CarcinomaPromote immunity (T cell function)While expression of CXCL12(P2G) significantly inhibited metastasis, expression of wild-type CXCL12 potently inhibited both metastasis and primary tumor growth. The effects of wild-type CXCL12 were attributed to an immune response characterized by the induction of CD8+ T cell activity, enhanced cell-mediated cytotoxicity, increased numbers of CD11c+ cells in the tumor-draining lymph nodes and reduced accumulation of myeloid-derived suppressor cells in the spleen
23891972Pancreatic Ductal AdenocarcinomaPromote immunity (T cell function)In vitro migration assays showed that CD8(+) T cells, from patients with PDAC, had increased chemotaxis toward activated PSCs, which secrete CXCL12, compared with quiescent PSCs or tumor cells. These effects could be reversed by knockdown of CXCL12 or treatment of PSCs with ATRA.
21521526Basal-Like Breast CarcinomaInhibit immunity (infiltration)High Treg infiltration correlated with tumour CXCL12 positivity (OR 1.89, 95% CI 1.22 to 2.94, P = 0.004) and basal phenotype (OR 3.14, 95% CI 1.08 to 9.17, P = 0.004) in univariate and multivariate analyses. CXCL12 positivity correlated with improved survival (P = 0.005), whereas high Treg correlated with shorter survival for all breast cancers (P = 0.001), luminal cancers (P < 0.001) and basal-like cancers (P = 0.040) that were confirmed in a multivariate analysis (OR 1.61, 95% CI 1.02 to 2.53, P = 0.042). Our data show that in the setting of hypoxia and CXCR4 up-regulation in Treg, CXCL12 expression may have the negative consequence of enhancing Treg recruitment and suppressing the anti-tumour immune response.
28809532Pancreatic CarcinomaInhibit immunity (infiltration)We also found that CXCL12 trap allowed T-cell penetration into the tumor
24277834Pancreatic Ductal AdenocarcinomaInhibit immunity; Resistant to immunotherapyTargeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Administering AMD3100, a CXCL12 receptor chemokine (C-X-C motif) receptor 4 inhibitor, induced rapid T-cell accumulation among cancer cells and acted synergistically with α-PD-L1 to greatly diminish cancer cells, which were identified by their loss of heterozygosity of Trp53 gene. Thus, a single protein, CXCL12, from a single stromal cell type, the FAP(+) CAF, may direct tumor immune evasion in a model of human PDA.
21742774Ovarian CarcinomaInhibit immunityCXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. siRNA-mediated knockdown of CXCL12 in BR5-1 cells that constitutively express CXCL12 and CXCR4 reduced cell proliferation in vitro, and tumor growth in vivo.
29735547OsteosarcomaPromote immunity (infiltration)Here we show for the first time that osteosarcomas epigenetically downregulate CXCL12 expression via DNA methyltransferase 1 (DNMT1) and consequently acquire the ability to metastasize and impair cytotoxic T-cell homing to the tumor site. Evaluations on fresh human chemotherapy-free osteosarcoma samples also showed a positive correlation between CXCL12 concentration and the number of intratumoral lymphocytes.
16990769leukemiaPromote immunity(infiltration)Anti-BCP-ALL T cells expressed CD49d and CXCR4 (implicated in the recruitment to bone marrow), and CD62L and CCR7 (involved in the migration to lymphoid organs). In accordance with this profile, T cells significantly migrated in response to the chemokines CXCL12 and CCL19.
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL12 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3630.464
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4970.858
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2490.889
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0320.964
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4750.834
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5320.856
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5830.393
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0770.558
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0820.97
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4380.834
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0010.478
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3460.113
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL12.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL12 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL12 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL12
Namechemokine (C-X-C motif) ligand 12
Aliases SCYB12; SDF-1a; SDF-1b; PBSF; TLSF-a; TLSF-b; TPAR1; SDF1A; SDF1B; SDF1; stromal cell-derived factor 1; IRH; ......
Chromosomal Location10q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL12 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CXCL12.
ID Name Drug Type Targets #Targets
DB06822TinzaparinSmall MoleculeCXCL12, ITGA4, SERPINC13